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Introduction 
 
Space flight has many adverse effects on human physiology. Changes in multiple 
systems, including the cardiovascular, musculoskeletal, neurovestibular, endocrine, and immune 
systems have occurred (12, 32, 38, 39). Alterations in drug pharmacokinetics and 
pharmacodynamics (12), nutritional needs (31), renal stone formation (40), and microbial flora 
(2) have also been reported. Evidence suggests that the magnitude of some changes may increase 
with time in space. 
 
A variety of changes in immunity have been reported during both short (≤16 days) and 
long (>30 days) space missions. However, it is difficult to determine the medical significance of 
these immunological changes in astronauts. Astronauts are in excellent health and in superb 
physical condition. Illnesses in astronauts during space flight are not common, are generally 
mild, and rarely affect mission objectives. In an attempt to clarify this issue, we identified the 
latent herpes viruses as medically important indicators of the effects of space flight on immunity. 
This chapter demonstrates that space flight leads to asymptomatic reactivation of latent herpes 
viruses, and proposes that this results from marked changes in neuroendocrine function and 
immunity caused by the inherent stressfulness of human space flight. 
 
Astronauts experience uniquely stressful environments during space flight. Potential 
stressors include confinement in an unfamiliar, crowded environment, isolation, separation from 
family, anxiety, fear, sleep deprivation, psychosocial issues, physical exertion, noise, variable 
acceleration forces, increased radiation, and others. Many of these are intermittent and variable 
in duration and intensity, but variable gravity forces (including transitions from launch 
acceleration to microgravity and from microgravity to planetary gravity) and variable radiation 
levels are part of each mission and contribute to a stressful environment that cannot be 
duplicated on Earth. Radiation outside the Earth’s magnetosphere is particularly worrisome 
because it includes ionizing radiation from cosmic galactic radiation. Increased stress levels 
appear even before flight, presumably from the rigors of preflight training and the anticipation of 
the mission (12, 32, 38, 39). 
 
Space flight causes significant changes in human immune function (32), but the means by 
which these changes come about have been difficult to discern. Consistent indicators of stress 
associated with space flight include increased production of stress hormones, and changes in 
cells of the immune system. These changes include elevated white blood cell (WBC) and 
neutrophil counts at landing (15, 16, 35, 37). Activation of generalized stress responses before, 
during, and after space flight probably affects the function of the immune system. Space flight 
has been shown to decrease many aspects of immune function, including natural killer (NK) cell 
activity, interferon production, the blastogenic response of leukocytes to mitogens, cell-mediated 
immunity, neutrophil function and monocyte function (5, 16, 18, 21, 35-37).  
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 REACTIVATION OF LATENT HERPES VIRUSES 
 
Latent viruses are used as an early predictor of changes in immune system of astronauts 
due to space flight.  Humans host 8 different herpes viruses. Following primary infection, these 
viruses establish a permanent presence with the host called latency.  The virus may remain latent 
and unnoticed for years or decades.  Cell mediated immunity (CMI) is the immune element most 
responsible for controlling latent viruses. During times of stress, latent viruses may reactivate 
and cause disease. Stress is processed through the Hypothermus pituitary adrenal (HPA) axis and 
sypamathetic adrenalmedullary axis, resulting in increased secretion of stress hormones 
including cortisol and catecholamines (8, 9, 11). Increased levels of stress hormones reduce the 
immune response, specifically the CMI resulting in proliferation of latent viruses and disease at a 
later stage.   
 
Astronauts experience various stressors that may result in inhibition of their cell-
mediated immunity and increased reactivation of latent viruses during space flight, potentially 
increasing the risk of disease among crew members. Risks associated with many infectious 
agents are reduced by restricting preflight contact of the flight crews with high-risk populations. 
However, the risk of latent virus reactivation is unaffected by such precautions. Virus 
reactivation could pose an important health risk for astronauts, as well as for people living and 
working in other extreme environments. In this paper, we present the results from our studies of 
reactivation of three latent herpes viruses (Epstein Barr Virus, Cytomegalovirus, Varicella Zoster 
Virus) in astronauts and discuss our interpretation of these results. 
 
 
Epstein-Barr Virus 
Epstein-Barr virus (EBV), a DNA virus is highly infectious and can be transmitted by 
microdroplets and by direct contact with saliva. When the acute infectious phase subsides, EBV 
can become latent in B lymphocytes. EBV is the causative agent of infectious mononucleosis 
and is associated with several malignancies, including Burkitt’s lymphoma, nasopharyngeal 
carcinoma, and diffuse oligoclonal B-cell lymphoma (1, 13, 14, 19, 26, 30). Latent EBV may be 
reactivated by a range of physical and psychosocial stress factors and shed in saliva (10, 11).  
EBV was used as a model for latent virus reactivation in astronauts.  Approximately 95% 
of the adult population is infected by EBV (19, 27). This makes EBV ideal for studying virus 
reactivation in the relatively small astronaut population.  Pierson et al., (28) collected and used a 
PCR assay to detect EBV DNA and demonstrate EBV reactivation in shuttle astronauts.  Pierson 
et al. (29) demonstrated EBV DNA shed in saliva from astronauts before, during, and after space 
flight. EBV copies were about 10-fold higher during the flight phase than shed either before or 
after space flight ( Figure 1). In addition, the number of EBV copies shed during space flight 
seemed to increase as a function of time in space.  A significant increase in EBV (VCA) 
antibody titers before launch, at landing, and after landing was observed (p < 0.001) from the 
baseline values taken 5 to 24 months before flight. These findings are consistent with reports by 
Stowe et al. (34). 
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Cytomegalovirus 
 
To determine if the effects of space flight observed in astronauts were limited to EBV, we 
studied another human herpes virus, cytomegalovirus (CMV).  When CMV reactivates, it is shed 
in urine. CMV DNA was found in astronaut urine collected before and after flight.  Figure 2 
shows that 27% (15/55) of astronauts shed CMV in their urine while less than 2 per cent (1 of 
61) of control subjects shed CMV (23).  Plasma IgG antibodies to CMV increased significantly 
as compared to the controls in astronauts who shed CMV, confirming reactivation of the virus 
(Figure 3).  
 
Varicella Zoster Virus 
Subsequently, varicella zoater virus (VZV) was found in saliva of shuttle astronauts 
during and after space flight (Figure 3).  This was the first report of shedding of VZV with no 
clinical symptoms.  As expected, no shedding was found in control subjects. VZV antibodies 
also increased over control values substantiating occurrence of VZV reactivation.  Consistent 
with findings from EBV and CMV studies, urinary cortisol levels increased in astronauts at 
landing.  Further descriptions of CMV and VZV reactivation in astronauts are given by Mehta et 
al. (20, 23). Table 3 summarizes the data available on viral reactivation in astronauts. 
All available data suggest that stress, and perhaps other factors, are processed through the 
HPA axis.  Levels of stress hormones, including cortisol and catecholamines, in astronauts were 
consistently elevated at landing. Elevations in these hormones result in diminished CMI 
response, and decreased CMI is followed by increased reactivation and shedding of latent herpes 
viruses.   
Having shown that either stress or environmental factors associated with space flight can 
trigger VZV reactivation detected as viral DNA in saliva, we refocused our research to determine 
if VZV reactivation constitutes a health risk to astronauts. Our approach was to demonstrate the 
propagation of infectious VZV from astronauts’ saliva after space flight. First, however, we 
asked if VZV can remain infectious after being exposed to human saliva.  
 
Saliva taken 2-6 days after landing from 3 subjects was cultured on human fetal lung 
cells (Figure 4).  Infectious VZV was recovered from saliva of subjects 1 and 2 on the second 
day after landing.  Virus specificity was confirmed by antibody staining and DNA analysis 
which showed it to be VZV of European descent, common in the US.  Further, both antibody 
staining and DNA PCR demonstrated that no HSV-1 was detected in any infected culture (4). 
 
IgG antibody against VZV was determined by enzyme immunoassay (EIA) (6, 7). Serum 
titers of anti-VZV IgG were determined in 5 control subjects and in 6 astronauts 10 days before 
flight and again 2 to 3 hours after landing (Figure 5). We found two- to three-fold greater levels 
of circulating anti-VZV IgG in astronauts than in control subjects. However, the combination of 
VZV DNA in saliva and a larger specific antibody response in serum from astronauts than in 
serum from control subjects further indicates sub-clinical reactivation of VZV. This study adds 
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VZV to the list of human herpes viruses capable of reactivation in response to acute non-surgical 
stress. 
 
HSV types 1 and 2 were detected in 2 to 3% of pre- and postflight and in 8% of in-flight 
saliva samples collected from space shuttle crew members.  HHV-6 was detected in 29% of 
preflight, 2% of in-flight, and 15% of postflight samples (Pierson et al., unpublished data).   
 
   
Selected neuropeptides, including SP, CGRP, Neuropeptide Y, and VIP, were also 
measured in plasma from 5 astronauts before and after space flight. They were elevated 
immediately after landing (Figure 6). This is consistent with the decrease in cell-mediated 
immunity (CMI) reported earlier in astronauts (37) and Antarctic expeditioners (22, 25), and 
therefore is consistent with an increase in viral reactivation (28). However, until neuropeptide 
data can be obtained from a larger number of astronauts, the significance of changes in astronaut 
neuropeptide levels cannot be adequately assessed.  
   
 
Medical Significance of Latent Virus Reactivation in Space Flight 
 
The medical significance of asymptomatic viral shedding in astronauts remains unknown. 
During the flight phase, the mean number of EBV DNA copies shed by astronauts was 417/mL, 
with a maximum of 738/mL. In the saliva of acquired immunodeficiency syndrome (AIDS) 
patients, we found 3700 copies/mL (mean value) of EBV DNA. However, some AIDS patients 
had levels as low as 600 copies. Kimura (17), who used a similar PCR assay, reported that a 
group of patients with infectious mononucleosis had a mean number of 158 copies of EBV DNA 
per mL of saliva.  
 
In renal transplant recipients with active CMV infection, Stagno et al. (33) found that the 
number of CMV genomes per mL of urine was 100-fold greater in symptomatic patients than in 
asymptomatic patients. The number of EBV copies found in astronaut saliva indicated that the 
diminishment of immune response is very mild on short shuttle flights and cannot be compared 
to that of patients with severely impaired immunity (such as AIDS patients). However, lengthy 
stays in space may result in substantial reductions in immunity, and the number of EBV copies in 
saliva of cosmonauts aboard the Mir space station is consistent with this scenario. 
 
The increased amount of EBV DNA in saliva, coupled with the propensity of large and 
small saliva droplets to float in the microgravity environment of the crew compartment, may lead 
to increased risk of cross-infection among crew members. One would expect minimal medical 
effects of such events in healthy individuals, but viral reactivation is more likely to have clinical 
significance (3) for astronauts if their immune responses are impaired.  
 
Recently we reported that salivary VZV DNA was associated with the severity of disease in 
shingle patients (24). Fifty-four zoster patients were treated with valacyclovir.  On treatment day 1, 7- and 
14-days later, pain was scored and saliva examined for VZV-DNA.  VZV-DNA was found in every 
patient the day treatment was started and disappeared in 82%.  There was a positive correlation between 
presence of VZV-DNA and pain, and between VZV-DNA copy number and pain (P<0.0005).  VZV-
DNA was present in one patient before rash, in 4 after pain resolved, and not in any of 6 subjects with 
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chronic pain or 14 healthy subjects.  Analysis of human saliva has potential usefulness in diagnosing 
neurological disease produced by VZV without rash. 
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Figure Legends 
 
 
FIGURE 1. Distribution of the number of EBV DNA copies per mL of saliva in EBV-
positive samples from 32 astronauts during sampling periods before, during, and after 10 space 
shuttle missions. Though each dot represents an EBV-positive sample, some dots overlap. 
Therefore, the number of dots should not be used to calculate the number of positive samples.  
 
 
FIGURE 2. Percentage of subjects (55 astronauts, 61 controls) who shed CMV DNA in 
urine samples collected before, during, and after short-duration space flights.  
 
FIGURE 3. Cytomegalovirus (CMV) IgG antibody titer (mean log2 ± SE) in astronaut 
blood samples at baseline (BL), 10 days before launch (L–10), and at landing (R+3). *Significant 
increase from BL (P<0.001); †significant increase from L-10 (P< 0.001).  
 
 
FIGURE 4. Plaque morphology as an indicator of the susceptibility to VZV infection of 
two types of indicator cells, primary human lung fibroblast (HLF, upper panel) and human 
malignant melanoma (MeWo, lower panel) cells. Sub-confluent monolayers of MeWo and HLF 
cells were infected with identical amounts of cell-free VZV. After 5 days of incubation, the 
cultures were fixed and stained to reveal VZV cytopathology (open arrows).  
 
FIGURE 5. Antibody titer index of anti-VZV antibody in astronauts before and after 
space flight and in control subjects. IgG antibody against VZV was determined by enzyme 
immunoassay (EIA). Serum titer of anti-VZV IgG was determined in 5 control subjects and in 6 
astronauts 10 days before flight (L–10) and again 2 to 3 hours after landing (R+0) P<0.001.  
 
 
FIGURE 6. Plasma concentration (mean ± SE) of neuropeptides in blood samples from 5 
astronauts at 3 times before and after a 5-day mission: 10 days before launch (L–10), at landing 
(R+0), and 3 days after landing (R+3). SP, substance P; CGRP, calcitonin gene-related peptide; 
NY, neuropeptide Y; VIP, vasoactive intestinal peptide. From Pierson et al. (2005, Fig. 4, p. 
239), with permission. 
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